Alexza Pharmaceuticals Inc. was incorporated on Dec. 19, 2000, as FaxMed Inc and later changed its name to Alexza Pharmaceuticals. The company is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system or CNS conditions. Alexza's primary activities since incorporation have been establishing its offices, recruiting personnel, conducting research and development, conducting preclinical studies and clinical trials, performing business and financial planning, and raising capital. Alexza Pharmaceuticals Inc. has a market cap of $73.1 million; its shares were traded at around $4.62 with and P/S ratio of 22.30.
On July 26, 2013, Pres & CEO of Alexza Pharmaceuticals Inc. (ALXA, Financial) Thomas Braxton King bought 40,000 shares of ALXA stock at an average price of $4.48. The total transaction amount was $179,200
Thomas B. King has been the President, CEO and member of Board of Alexza Pharmaceuticals since June 2003. Prior to joining this company, King served at Cognetix Inc. as CEO, president and a member of the board. He has also worked at Anesta Corporation and Cephalon Inc.
Alexza Pharmaceuticals Inc. reported its 2013 first financial quarter results. The company announced net loss of $20.7 million and revenues of $729,000.
On July 26, 2013, Pres & CEO of Alexza Pharmaceuticals Inc. (ALXA, Financial) Thomas Braxton King bought 40,000 shares of ALXA stock at an average price of $4.48. The total transaction amount was $179,200
Thomas B. King has been the President, CEO and member of Board of Alexza Pharmaceuticals since June 2003. Prior to joining this company, King served at Cognetix Inc. as CEO, president and a member of the board. He has also worked at Anesta Corporation and Cephalon Inc.
Alexza Pharmaceuticals Inc. reported its 2013 first financial quarter results. The company announced net loss of $20.7 million and revenues of $729,000.
